Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the pediatric oncology group

Strother, Douglas; Hoff, Jack van; Rao, Pejaver V.; Smith, E. Ide; Shamberger, Robert C.; Halperin, Edward C.; Murray, Kevin; Castleberry, Robert P.

doi:10.1016/s0959-8049(97)00293-1

Cited by 45 publications

(23 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is often preferable to use chemotherapy as the initial treatment in these patients aiming at reducing the tumor bulk, making complete removal more likely and the surgery safer. Data from POG in patients with stage 2B and stage 3 disease have shown that complete resection is not associated with a significantly better eventfree survival than incomplete resection, while patients with favorable Shimada histology have a significantly better event-free survival rate at 2 years than those with unfavorable Shimada (92% versus 58%, respectively) [17].…”

Section: More Advanced Operable Diseasementioning

confidence: 97%

“…As the chemotherapy protocol used in this study was less intensive than that now considered standard, it remains possible that more intensive chemotherapy might be as good as combined chemotherapy and radiotherapy in the POG trial. Based on the fact that patients with biologically favorable tumors have a good prognosis [20], even in the presence of residual disease, it is reasonable not to irradiate patients with biologically favorable stage 2B and stage 3 tumors, with or without residual disease after chemotherapy and surgery. Despite the adverse effects of radiotherapy in young children, it should be considered in the treatment plan of patients with biologically unfavorable stage 2B and stage 3 tumors with residual disease [21].…”

Section: More Advanced Operable Diseasementioning

confidence: 99%

See 1 more Smart Citation

Target Therapy in Neuroblastoma

Hassan¹,

Badr²,

Safy³

et al. 2017

Neuroblastoma - Current State and Recent Updates

View full text Add to dashboard Cite

Neuroblastoma is an embryonal malignancy that originates in the sympathetic nervous system. It is the most common solid tumor in infants and the most frequent extracranial solid tumor in children. Neuroblastoma accounts for 10% of childhood malignancies with 75% occurring in children <4 years. Stage, age, clinical and tumor genomic features are the principal criteria for determining treatment policy. Treatment modalities traditionally employed in the management of neuroblastoma are surgery, chemotherapy, and radiotherapy. Intensive multimodal treatment in patients with neuroblastoma has resulted in improved survival rates. However, there is a considerable percentage of patients with refractory and relapsed disease. Targeted therapy for neuroblastoma involves treatment aimed at molecular targets that have a unique expression in this childhood cancer. A large number of molecular targets have been identified for the treatment of high-risk and relapsed neuroblastoma. Treatment in this way aims at providing a more selective way to treat the disease and decreasing toxicities associated with the conventional treatment regimen.

show abstract

Section: More Advanced Operable Diseasementioning

confidence: 97%

Section: More Advanced Operable Diseasementioning

confidence: 99%

Target Therapy in Neuroblastoma

Hassan¹,

Badr²,

Safy³

et al. 2017

Neuroblastoma - Current State and Recent Updates

View full text Add to dashboard Cite

show abstract

“…Several studies have also shown similar outcomes for patients with stages 2 and 3 with favorable biology regardless of the degree of tumor resection. 63,[71][72][73][74] For the minority of patients whose disease recurs or progresses, and is not completely resectable, use of chemotherapy is effective salvage therapy. 75 The current COG strategy is to stratify stage 1 patients by extent of surgery.…”

Section: Low Riskmentioning

confidence: 99%

Neuroblastoma

Esiashvili

Anderson

Katzenstein

2009

Current Problems in Cancer

View full text Add to dashboard Cite

Neuroblastoma N euroblastoma (NB) is the most common extracranial solid tumor of childhood and the most common tumor in infants. Over the last 2 decades, a tremendous amount of progress has been made in the understanding of NB biology; however, there are multiple challenges remaining so that we can successfully combat this disease. NB remains one of the most enigmatic pediatric tumors, displaying a wide variety of clinical behavior from spontaneous regression and differentiation to very aggressive behavior with rapid growth and spread. This article is aimed at providing a systematic review of NB: outlining disease characteristics, highlighting current treatment strategies and challenges, and providing potential areas of direction that may yield further improvement in the outcome of these patients.

show abstract

“…Because the patient was diagnosed at the age of 23 months and evaluated as having stage 2B disease (unilateral with complete gross resection, with ipsilateral lymph node positive for tumor and identifiable contralateral lymph node negative for tumor) according to the International Neuroblastoma Staging System (INSS) staging [7], with nonamplified MYCN (determined by fluorescence in situ hybridization test) and unfavorable histology (neuroblastoma, poorly differentiated subtype with a low mitosis-karyorrhexis index, according to the International Neuroblastoma Pathology Classification), the case was classified into a low-risk group according to the current risk scheme used by the Children's Oncology Group) Neuroblastoma Biology Study [8]. Accordingly, the patient was clinically observed without chemotherapy/radiation therapy after the surgery [9]. She will be observed closely at our institution for signs or symptoms of recurrence.…”

Section: Case Reportmentioning

confidence: 99%